The Department of Energy Office of Nuclear Energy acting assistant secretary makes his first visit to a national laboratory in his new role, touring PNNL's Radiochemical Processing Laboratory.
The SHASTA program is doing a deep dive on subsurface hydrogen storage in underground caverns, helping to lay the foundation for a robust hydrogen economy.
Identifying how curvature affects the doping and hydrogen binding energies of carbon-based materials provides a framework for designing hydrogen storage materials.
An initiative from Washington State University and Snohomish County leaders is aiming to make Paine Field a nexus for testing and improving sustainable aviation fuels made from non-petroleum materials.
Scientists screen for nanobodies that recognize wild type and mutant functional proteins to develop a framework to disrupt protein interactions that can cause disease.
PNNL is honoring its postdoctoral researchers as part of the fourteenth annual National Postdoc Appreciation Week with seven profiles of postdocs from around the Laboratory.
COVID-19 infections at PNNL early in the pandemic were caused by a wide variety of viral sequences, according to a new analysis by Laboratory researchers.
SAGE is a high-efficiency genome integration strategy for bacteria that makes the stable introduction of new traits simple for newly discovered microbes.
A PNNL innovation uses steam to recover heat from the high-temperature reactor effluent in the HTL process, substantially reducing the propensity for fouling and potentially reducing costs.
Patented microchannel heat-exchange technology enables the production of hydrogen from methane, the main ingredient of natural gas, while producing 30 percent less carbon dioxide than conventional processes.
A PNNL-developed computational framework accurately predicts the thermomechanical history and microstructure evolution of materials designed using solid phase processing, allowing scientists to custom design metals with desired properties.
Gosline works to develop computational algorithms that are uniquely targeted for rare disease work by doing foundational research in model system development. This work can be expanded to all model systems in human disease.